AbbVie Showcases New Data Supporting Premier Gastroenterology Portfolio at 2024 Digestive Disease Week

AbbVie (NYSE: ABBV) announced it will present 15 abstracts at the 2024 Digestive Disease Week (DDW) Annual Meeting, occurring May 18-21 in Washington, D.C., and virtually.

“At DDW, AbbVie is presenting research demonstrating rapid symptom relief and notable improvements in the GI tract from our portfolio,” said Andrew Anisfeld, Ph.D., Vice President, Global Medical Affairs, Immunology, AbbVie. “Our work aims to enhance the standard of care for IBD patients, addressing both immediate and long-term health goals measurable by healthcare teams.”

As a gastroenterology leader, AbbVie focuses on opportunities to advance IBD understanding through its diverse portfolio, encompassing marketed and investigational products. The research presented at DDW will highlight risankizumab (SKYRIZI®) and upadacitinib (RINVOQ®) for IBD treatment.

Key presentations include:

• Risankizumab vs. Ustekinumab in Crohn’s Disease (SEQUENCE Trial): Evaluating risankizumab’s efficacy compared to ustekinumab in achieving STRIDE-II goals in moderate-to-severe Crohn’s disease patients.
• Risankizumab in Ulcerative Colitis (COMMAND Study): Assessing corticosteroid-free outcomes in moderately to severely active ulcerative colitis.
• Risankizumab Maintenance Therapy in Ulcerative Colitis (COMMAND Study): Investigating the long-term safety and efficacy of risankizumab maintenance therapy.
• Upadacitinib Therapy in Ulcerative Colitis: Exploring two-year corticosteroid-free remission in moderately to severely active ulcerative colitis.
• Effect of Upadacitinib on Lipid Profiles in IBD: Analyzing the impact on lipid profiles from pooled data of Phase 3 studies in Crohn’s disease and ulcerative colitis.

AbbVie’s DDW 2024 presentation schedule includes:

Risankizumab Presentations:

1. Efficacy and Safety in Crohn’s Disease (FORTIFY Study): May 19, 12:30-1:30 PM (Poster #Su1761).
2. Clinical Remission in Crohn’s Disease (SEQUENCE Trial): May 20, 2:00-3:30 PM (Oral Presentation #763).
3. Cost Analysis in Crohn’s Disease (SEQUENCE Trial): May 21, 12:30-1:30 PM (Poster #Tu1095).
4. Outcomes in Ulcerative Colitis (INSPIRE Study): May 19, 12:30-1:30 PM (Poster #Su1773).
5. Placebo Maintenance in Ulcerative Colitis (COMMAND Study): May 19, 12:30-1:30 PM (Poster #Su1792).
6. Corticosteroid-Free Outcomes in Ulcerative Colitis (COMMAND Study): May 19, 12:30-1:30 PM (Poster #Su1751).
7. Symptom Improvement in Ulcerative Colitis (INSPIRE Study): May 19, 12:30-1:30 PM (Poster #Su1770).
8. Additional Therapy in Non-Responders (INSPIRE and COMMAND Studies): May 20, 4:00-5:30 PM (Oral Presentation #904).
9. Economic Impact in Ulcerative Colitis (Phase 3 Study): May 21, 12:30-1:30 PM (Poster #Tu1102).
10. Maintenance Therapy in Ulcerative Colitis (COMMAND Study): May 21, 8:00-9:30 AM (Oral Presentation #984).

Upadacitinib Presentations:

1. Clinical and Endoscopic Outcomes: May 19, 12:30-1:30 PM (Poster #Su1792).
2. Quality of Life Improvements: May 19, 12:30-1:30 PM (Poster #Su1863).
3. Long-term Extension in Crohn’s Disease (U-ENDURE Study): May 19, 12:30-1:30 PM (Poster #1798).
4. Lipid Profile Impact in IBD: May 19, 12:30-1:30 PM (Poster #Sa1757).
5. Corticosteroid-Free Remission in Ulcerative Colitis: May 19, 12:30-1:30 PM (Poster #Su1786).

For more detailed program information, please refer to the 2024 DDW Annual Meeting program.

Source Link